Literature DB >> 12817032

More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice.

Christian Seifarth1, Shannon Pop, Bo Liu, Carmen P Wong, Roland Tisch.   

Abstract

Recurrent autoimmune destruction of the insulin-producing beta cells is a key factor limiting successful islet graft transplantation in type I diabetic patients. In this study, we investigated the feasibility of using an Ag-specific plasmid DNA (pDNA)-based strategy to protect pro-islets that had developed from a neonatal pancreas implanted under the kidney capsule of nonobese diabetic (NOD) mice. NOD recipient mice immunized with pDNA encoding a glutamic acid decarboxylase 65 (GAD65)-IgFc fusion protein (JwGAD65), IL-4 (JwIL4), and IL-10 (pIL10) exhibited an increased number of intact pro-islets expressing high levels of insulin 15 wk posttransplant, relative to NOD recipient mice immunized with pDNA encoding a hen egg lysozyme (HEL)-IgFc fusion protein (JwHEL)+JwIL4 and pIL10 or left untreated. Notably, the majority of grafted pro-islets detected in JwGAD65+JwIL4- plus pIL10-treated recipients was free of insulitis. In addition, administration of JwGAD65+JwIL4+pIL10 provided optimal protection for engrafted islets compared with recipient NOD mice treated with JwGAD65+JwIL4 or JwGAD65+pIL10, despite effective protection of endogenous islets mediated by the respective pDNA treatments. Efficient protection of pro-islet grafts correlated with a marked reduction in GAD65-specific IFN-gamma reactivity and an increase in IL-10-secreting T cells. These results demonstrate that pDNA vaccination can be an effective strategy to mediate long-term protection of pro-islet grafts in an Ag-specific manner and that conditions are more stringent to suppress autoimmune destruction of grafted vs endogenous islets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817032     DOI: 10.4049/jimmunol.171.1.469

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.

Authors:  Tatiana Takiishi; Hannelie Korf; Tom L Van Belle; Sofie Robert; Fabio A Grieco; Silvia Caluwaerts; Letizia Galleri; Isabella Spagnuolo; Lothar Steidler; Karolien Van Huynegem; Pieter Demetter; Clive Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Conny Gysemans; Chantal Mathieu
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

Review 2.  Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.

Authors:  Mark C Johnson; Bo Wang; Roland Tisch
Journal:  Hum Vaccin       Date:  2011-01-01

3.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

Review 6.  Manipulating the type 1 vs type 2 balance in type 1 diabetes.

Authors:  Urs Christen; Matthias G von Herrath
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice.

Authors:  Kevin S Goudy; Bo Wang; Roland Tisch
Journal:  Clin Immunol       Date:  2008-10       Impact factor: 3.969

8.  Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.

Authors:  Damien Bresson; Matthew Fradkin; Yulia Manenkova; Diane Rottembourg; Matthias von Herrath
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

9.  Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.

Authors:  Li Li; Zuoan Yi; Bo Wang; Roland Tisch
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

Review 10.  Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.

Authors:  Charles J Kroger; Matthew Clark; Qi Ke; Roland M Tisch
Journal:  Front Immunol       Date:  2018-08-16       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.